The Carlyle Group Inc. 4.625% Subordinated Notes due 2061 (CGABL)vsVertex Pharmaceuticals Inc (VRTX)
CGABL
The Carlyle Group Inc. 4.625% Subordinated Notes due 2061
$17.50
+1.39%
NONE · Cap: $16.14B
VRTX
Vertex Pharmaceuticals Inc
$427.38
+0.98%
HEALTHCARE · Cap: $108.71B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 32.9% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
CGABL
Avoid30
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CGABL.
Margin of Safety
+56.2%
Fair Value
$976.24
Current Price
$427.38
$548.86 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 69 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CGABL
The strongest argument for CGABL centers on Return on Equity.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : CGABL
The primary concerns for CGABL are Revenue Growth, EPS Growth, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CGABL profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Monitor NONE industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VRTX scores higher overall (66/100 vs 30/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
The Carlyle Group Inc. 4.625% Subordinated Notes due 2061
NONE · NONE · USA
The Carlyle Group Inc. 4.625% Subordinated Notes due 2061 present a compelling fixed-income investment opportunity from one of the world's leading investment firms, renowned for its expertise across private equity, credit, and real assets. Offering a competitive yield, these subordinated notes allow institutional investors to leverage Carlyle's strong market position and commitment to strategic growth and operational efficiency. As the firm continues to expand its global footprint and enhance its portfolio management capabilities, these notes are well-positioned to provide a stable source of long-term income within a resilient and diversified capital structure.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other NONE Stocks
Want to dig deeper into these stocks?